Leerink Partnrs Weighs in on Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Analysts at Leerink Partnrs issued their FY2025 EPS estimates for Zura Bio in a research report issued to clients and investors on Sunday, November 23rd. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.77) for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Leerink Partnrs also issued estimates for Zura Bio’s Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.17) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($0.75) EPS.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02).

ZURA has been the subject of several other research reports. Oppenheimer decreased their price target on shares of Zura Bio from $17.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, August 15th. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a research note on Friday, November 14th. HC Wainwright dropped their price target on Zura Bio from $3.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 19th. Wall Street Zen cut Zura Bio from a “hold” rating to a “sell” rating in a research note on Sunday, November 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zura Bio has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Price Performance

Shares of NASDAQ:ZURA opened at $3.75 on Wednesday. The firm’s 50 day simple moving average is $3.54 and its 200 day simple moving average is $2.19. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $4.68. The company has a market capitalization of $243.83 million, a price-to-earnings ratio of -5.77 and a beta of 0.24.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE lifted its position in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after buying an additional 9,966 shares in the last quarter. Scientech Research LLC bought a new position in Zura Bio during the third quarter worth $45,000. Savant Capital LLC lifted its position in Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after acquiring an additional 21,249 shares during the last quarter. Forefront Wealth Partners LLC bought a new position in Zura Bio during the 3rd quarter worth $93,000. Finally, Armistice Capital LLC raised its stake in Zura Bio by 1.6% in the 3rd quarter. Armistice Capital LLC now owns 1,560,000 shares of the company’s stock worth $6,755,000 after purchasing an additional 24,000 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.